Advancements in molecular design and bioprocessing of recombinant adeno‐associated virus gene delivery vectors using the insect‐cell baculovirus expression platform
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Despite rapid progress in the field, scalable high‐yield production of adeno‐associated virus (AAV) is still one of the critical bottlenecks the manufacturing sector is facing. The insect cell‐baculovirus expression vector system (IC‐BEVS) has emerged as a mainstream platform for the scalable production of recombinant proteins with clinically approved products for human use. In this review, we provide a detailed overview of the advancements in IC‐BEVS for rAAV production. Since the first report of baculovirus‐induced production of rAAV vector in insect cells in 2002, this platform has undergone significant improvements, including enhanced stability of Bac‐vector expression and a reduced number of baculovirus‐coinfections. The latter streamlining strategy led to the eventual development of the Two‐Bac, One‐Bac, and Mono‐Bac systems. The one baculovirus system consisting of an inducible packaging insect cell line was further improved to enhance the AAV vector quality and potency. In parallel, the implementation of advanced manufacturing approaches and control of critical processing parameters have demonstrated promising results with process validation in large‐scale bioreactor runs. Moreover, optimization of the molecular design of vectors to enable higher cell‐specific yields of functional AAV particles combined with bioprocess intensification strategies may also contribute to addressing current and future manufacturing challenges.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nucleotide sequence and organization of the adeno-associated virus 2 genome
Srivastava, A., Lusby, E. W., & Berns, K. I. (1983) · Journal of Virology · doi:10.1128/jvi.45.2.555-564.1983 · Cited by 721 · cited 4×
“Thewild-typeAAV (wtAAV) genome is a linear, single-strandedDNA with a size of approximately 4.7 Kb.[32] Major coding regions consist of the genes responsible for the expression of non-structural regulatory Rep proteins and structural capsid proteins (Cap or VP).”
BackgroundInfluentialGirod, A., Wobus, C. E., Zádori, Z., Ried, M., Leike, K., Tijssen, P., Kleinschmidt, J. A., & Hallek, M. (2002) · Journal of General Virology · doi:10.1099/0022-1317-83-5-973 · Cited by 354 · cited 1×
“[32] Sufficient expression and subsequent incorporation of VP1 subunit, harboring phospholipase A2 (PLA2) like enzymatic domain, in the AAV capsid are critical as the PLA2 is reportedly responsible for late endosomal escape and consequent perinuclear localization which are essential steps for the transduction efficien…”
MethodDNA helicase‐mediated packaging of adeno‐associated virus type 2 genomes into preformed capsids
King, J. A., Dubielzig, R., Grimm, D., & Kleinschmidt, J. A. (2001) · The EMBO Journal · doi:10.1093/emboj/20.12.3282 · Cited by 338
Manufacturing and characterizing AAV-based vectors for use in clinical studies
Wright, J. F. (2008) · Gene Therapy · doi:10.1038/gt.2008.65 · Cited by 205
Lessons learned from the clinical development and market authorization of Glybera
Bryant, L. M., Christopher, D. M., Giles, A. R., Hinderer, C., Rodriguez, J. L., Smith, J. B., Traxler, E. A., Tycko, J., Wojno, A. P., & Wilson, J. M. (2013) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2013.087 · Cited by 189
Grieger, J. C., Snowdy, S., & Samulski, R. J. (2006) · Journal of Virology · doi:10.1128/jvi.02723-05 · Cited by 172 · cited 1×
“[32] Sufficient expression and subsequent incorporation of VP1 subunit, harboring phospholipase A2 (PLA2) like enzymatic domain, in the AAV capsid are critical as the PLA2 is reportedly responsible for late endosomal escape and consequent perinuclear localization which are essential steps for the transduction efficien…”
MethodRumachik, N. G., Malaker, S. A., Poweleit, N., Maynard, L. H., Adams, C. M., Leib, R. D., Cirolia, G., Thomas, D., Stamnes, S., Holt, K., et al. (2019) · doi:10.1101/640169 · Cited by 156
Ruffing, M., Zentgraf, H., & Kleinschmidt, J. A. (1992) · Journal of Virology · doi:10.1128/jvi.66.12.6922-6930.1992 · Cited by 109 · cited 1×
“Ruffing et al.[30] in 1992 reported baculovirus-mediatedAAV cap gene delivery, VP proteins expression, and capsids assembly in insect cells.”
BackgroundMietzsch, M., Casteleyn, V., Weger, S., Zolotukhin, S., & Heilbronn, R. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.050 · Cited by 65
Manufacturing Clinical Grade Recombinant Adeno-Associated Virus Using Invertebrate Cell Lines
Kotin, R. M., & Snyder, R. O. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.042 · Cited by 59
Cited by
Dobrowsky, T., Gianni, D., Pieracci, J., & Suh, J. (2021) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2021.100353 · Cited by 90
Azali, M. A., Mohamed, S., Harun, A., Hussain, F. A., Shamsuddin, S., & Johan, M. F. (2022) · Journal of Genetic Engineering and Biotechnology · doi:10.1186/s43141-022-00368-7 · Cited by 13
Gurazada, S. G. R., Kennedy, H. M., Braatz, R. D., Mehrman, S. J., Polson, S. W., & Rombel, I. T. (2025) · Biotechnology Advances · doi:10.1016/j.biotechadv.2024.108506 · Cited by 9
Metadata
- Authors
- Joshi, P. R. H., Venereo‐Sanchez, A., Chahal, P. S., & Kamen, A. A.
- Venue
- Biotechnology Journal
- Publisher
- Wiley
- Published
- 2021-01-25
- Volume
- 16
- Issue
- 4
- Pages
- e2000021-e2000021
- ISSN
- 1860-6768 (ISSN-L)
- 1860-7314
- OpenAlex
- W3107760758
- Cited by
- 53
- References
- 11
- FWCI
- 2.01
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.